We thank Massart et al for their comments 1 on our recently published large-scale genome-wide association study of renal transplant outcomes, 2 and we welcome the opportunity to examine their findings in more detail. reaches a nominal level of statistical significance in either donor or recipient genome for our broader definition of acute rejection (any acute rejection event recorded in the first 12 months after transplantation).
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The genetic determinants of renal allograft rejection
To the Editor:
We thank Massart et al for their comments 1 on our recently published large-scale genome-wide association study of renal transplant outcomes, 2 and we welcome the opportunity to examine their findings in more detail. The lack of replication signal in our study, despite greater numbers of cases, may be due to a number of factors. We agree with Massart et al that one reason may be the differences in phenotype definition. Our study was primarily designed and powered to detect genetic variation in donor and recipient genomes associated with long-term graft survival, as this is the key unmet medical need in clinical renal transplantation outcomes, with currently no effective therapeutic options. Our acute rejection phenotype was established from reported national registry-based outcomes and was not specific to acute T cell-mediated rejection, and thus signal attenuation may be responsible for the difference. However, we note that in our study the recipient minor allele frequency differences between cases and controls are less than 1%, indicating almost complete attenuation.
Alternatively, it is possible that the signals found by Ghisdal et al 3 are false positives. Even genome-wide significant signals can be false positives, and as the authors used a pooled-DNA design, and employed a permutationbased joint test of association and linkage disequilibrium to determine the significance of hits in their discovery phase, it is difficult to determine the combined (discovery + replication) association p-values for their SNPs. We believe that further data are needed to resolve this issue.
We agree that genetic variation outside the HLA region is an important consideration in seeking to understand the pathogenesis of long-term graft survival and potentially identifying novel therapeutic targets to reduce cumulative allograft loss over time. We look forward to working with already established international collaborations 5 to identify these genetic determinants of long-term graft survival for the benefit of our patients. Neither SNP was found to be significantly associated with the acute rejection phenotype in our analysis, in either recipients or donors. The SNPs were imputed to the 1000 Genomes Phase 3 reference panel and analyzed using SNPTEST (frequentist 1, method score). The first 5 principal components, the recruitment site, recipient age, donor age, recipient sex, donor sex, and the total number of HLA mismatches (at A, B, and DR) were included as covariates. Both SNPs, in both recipients and donors, were imputed to a high quality, with an info score and average maximum posterior call of greater than 0.95. Test = recipient/donor to indicate whether recipient or donor genotypes were tested (null as missing /control indicates whether blank records were treated as missing data, or as controls); rsID, SNP identifier; alleleA, noneffect allele (coded as 0); alleleB, effect allele (coded as 1); cases/controls AA, number of case/controls who were homozygous for allele A; cases/controls AB, number of case/controls who heterozygous; cases/controls BB, number of case/controls who were homozygous for allele B; MAF, minor allele frequency (frequency of least common allele in the given dataset); beta, beta coefficient relating to the coded allele (alleleB); SE, standard error of beta coefficient; P, P-value.
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